Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

MEDI-528

Known as: Anti-IL9 Monoclonal Antibody MEDI-528, MEDI 528, MEDI-528, anti-IL-9 antibody 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Initially identified as a T cell and mast cell growth factor, interleukin (IL)-9 has long been recognized as an important… Expand
  • table I
  • table II
2017
2017
  • M. Wegmann
  • Expert review of respiratory medicine
  • 2017
  • Corpus ID: 27115523
Patients suffering from bronchial asthma display a number of symptoms including productive coughing, wheezing, chest tightness… Expand
Highly Cited
2013
Highly Cited
2013
BackgroundPreclinical studies suggest that interleukin-9 may be a central mediator in the development and maintenance of airway… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • table 2
Highly Cited
2011
Highly Cited
2011
BackgroundInterleukin-9 (IL-9)-targeted therapies may offer a novel approach for treating asthmatics. Two randomized placebo… Expand
  • figure 1
  • table 1
  • table 3
  • table 2
  • table 4
2010
2010
  • S. Antoniu
  • Current opinion in molecular therapeutics
  • 2010
  • Corpus ID: 23088594
In development by MedImmune LLC, under license from Genaera Corp, MEDI-528 is an injectable, humanized mAb against IL-9 for the… Expand
Highly Cited
2009
Highly Cited
2009
BACKGROUND Interleukin-9 (IL-9) is involved in pathogenic aspects of the asthmatic response, including induction of the… Expand
  • table I
  • figure 1
  • table II
  • figure 2
  • figure 3
2009
2009
UNLABELLED Population-based studies have established an association between migraine and cardiovascular disease (CVD). We sought… Expand
  • table 1
  • table 2
  • table 2
  • table 3